ReviewBrain sciences2020
Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies.
Review in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 57 citations in OpenAlex.
- Multiple Sclerosis: An Ethnically Diverse Disease with Worldwide Equity Challenges Accessing Care.Neurology international · 2025Article
- Clinical and epidemiological characteristics of multiple sclerosis in the southern region of the Republic of Azerbaijan.Pakistan journal of medical sciences · 2025Article
- Caregiver Involvement in MS: Duty or Disruption?Neurology and therapy · 2022Article
- Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia.Frontiers in immunology · 2022Article
- The Role of DCurrent neuropharmacology · 2022Article
- Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.Frontiers in immunology · 2022Review
- Gut Microbiota-Modulated Metabolomic Profiling Shapes the Etiology and Pathogenesis of Autoimmune Diseases.Microorganisms · 2021Review
- Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?International journal of molecular sciences · 2021Review
- The Core of Gut Life:Life (Basel, Switzerland) · 2021Article
- Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Evaluation of Lower Urinary Tract Dysfunction Impact on Quality of Life in Multiple Sclerosis Patients: Russian Translation and Validation of SF-Qualiveen.Multiple sclerosis international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Russian Federation, multiple sclerosis prevalence rates vary from 10 to 80 cases per 100,000, depending on region and the nationality of the population. The main characteristics of multiple sclerosis epidemiology in the XX century in this big territory are: (1) steady increase in multiple sclerosis prevalence and incidence rates, maybe because of better diagnosis and treatment, but also changes in environmental/epigenetic risk profile and/or lifestyle factors; (2) increase of the female to male ratio, increase in multiple sclerosis incidence mainly in females; (3) appearance and increasing frequency of multiple sclerosis in ethnic groups, previously free of multiple sclerosis (Northern Tribes, Yakuts and others). The latest data show that in European Russia, the multiple sclerosis prevalence varies from 30 to 80 cases, in Siberia-from 20 to 70 cases, with steady increases, especially in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.